Pursuant to Regulations 29 & 33 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR), GlaxoSmithKline Pharmaceuticals has informed that a meeting of the Board of Directors of our Company will be held on Monday, 3rd August 2026, to consider, approve and take on record the Un-audited financial results for the first quarter ended 30th June 2026.
The above information is a part of company’s filings submitted to BSE.